AI-generated analysis. Always verify with the original filing.
Avalo Therapeutics, Inc. announced its financial results for the year ended December 31, 2025, reporting a net loss of $78.3 million, research and development expenses of $50.1 million, and cash, cash equivalents, and short-term investments of $98.3 million expected to fund operations into 2028. Topline data from the Phase 2 LOTUS trial of abdakibart (AVTX-009) for hidradenitis suppurativa is expected in the second quarter of 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
(including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”) or o
Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press release, dated Marc h 23 , 202 6 . 104 Cover Page Interactive Data File (emb
| Metric | Value | Basis |
|---|---|---|
| Product Revenue, Net | $0.06 | GAAP |
| Research and Development | $50.08 | GAAP |
| General and Administrative | $22.90 | GAAP |
| Loss from Operations | $-72.93 | GAAP |
| Net Loss | $-78.26 | GAAP |
| Net Loss per Share - Basic | $-5.84 | GAAP |